Tamer Othman, M.D.

Publications

• Othman T#, Baird JH#, Wang Y, Pak S, Zhong H, Aldoss I, Cai J, Danilov A, Phillips TJ, Agrawal V, Sandhu KS, Mei M, Koller PB, Palmer J, Forman SJ, Budde LE, Aribi A. Outpatient Brexucabtagene Autoleucel in B-cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma. Accepted in Am J Hematol. In-press. #Contributed equally
• Muhsen IN, Roloff GW, Faramand RG, Othman T, Valtis YK, Kopmar NE, Dekker SE, Connor M, Mercadal S, O'Connor TE, Dykes KC, Ahmed M, Jeyakumar N, Zhang A, Miller K, Sutherland KC, Guzowski C, Gupta VK, Majhail NS, Battiwalla M, Solh MM, Malik SA, Mathews J, Oliai C, Shaughnessy PJ, Mountjoy L, Lee CJ, Logan AC, Tsai SB, Leonard JT, Schwartz MS, Sasine JP, Kumaran M, Frey NV, Park JH, Koura D, Cassaday RD, Shah BD, Aldoss I, Muffly LS, Hill LC. Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS Involvement. Blood Adv. 2025 May 7:bloodadvances.2024015779. Epub ahead of print. PMID: 40334068.
• Chehrazi-Raffle A, Zugman M, Ebrahimi H, Shodiya MO, Maldonado E, Othman T, Jaime- Casas S, Barragan-Carrillo R, Li X, Pal SK, Tripathi A, Zhumkhawala A, Hoeg R, Oliai C, Olin RL, Dorff TB, Mei M. Multicenter analysis of high-dose chemotherapy regimens for the treatment of patients with refractory or recurrent germ cell tumors. ESMO Open. 2025 May;10(5):105081. Epub 2025 May 1. PMID: 40315659.
• Othman T, Lo MM, Andreadis CB, Damon LE, Ferng TT, Gaensler KML, Lee JC, Martin TG, Olin RL, Sayre PH, Smith CC, Logan AC. Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma. Leuk Lymphoma. 2025 May 7:1-4. Epub ahead of print. PMID: 40329916.
• Lust H, Schultz LM, Kwon S, Roloff GW, Aldoss I, Baggott C, John S, Rossoff J, McNerney KO, Fabrizio VA, Talano JA, Moskop A, Curran KJ, Phillips CL, Karras NA, Baumeister SHC, Cooper S, Hermiston ML, Satwani P, Qayed M, Raikar SS, MacMillan ML, Hall EM, Nguyen K, Cassaday RD, Kopmar NE, Kota VK, Mathews J, Shaughnessy PJ, Schwartz MS, Ladha A, Yaghmour G, Kumaran M, Bachanova V, Tracy SI, Othman T, Luskin MR, Chen EC, Advani AS, Jeyakumar N, Miller K, Zhang A, Shah BD, Muffly LS, Faramand RG. Real World Outcomes for Young Adult Patients Receiving CD19 CAR T-cell Therapy. Blood Adv. 2025 Mar 24:bloodadvances.2024014846. Epub ahead of print. PMID: 40127395.
• Koller PB# , Othman T#, Yang D, Mokhtari S, Samara Y, Blackmon A, Agrawal V, Pourhassan H, Ball BJ, Amanam I, Arslan S, Otoukesh S, Sandhu KS, Aldoss I, Ali H, Salhotra A, Aribi A, Artz A, Becker PS, Pullarkat V, Stewart FM, Smith EP, Stein A, Marcucci G, Forman SJ, Nakamura R, Al Malki MM. Melphalan-based conditioning with post- transplant cyclophosphamide for peripheral blood stem cell transplantation: donor effect. Bone Marrow Transplant. 2025 May;60(5):625-631. PMID: 40016513. #Contributed equally
• Othman T, Marquez-Arreguin G, Esteghamat N, Tuscano J. A phase I trial of CC-486, lenalidomide, obinutuzumab in relapsed/refractory indolent non-Hodgkin lymphoma. Leuk Lymphoma. 2025 May;66(5):961-964. PMID: 39731545.
• Othman T, Logan AC, Muffly L, Leonard J, Park J, Shah B, Aldoss I. The Role of CAR T- Cell Therapy in Relapsed/Refractory Adult B-ALL. J Natl Compr Canc Netw. 2024 Oct;22(8):e247065. PMID: 39413830.
• Rahman ZA# , Othman T#, Saliba RM, Vanegas YAM, Mohty R, Ledesma C, Rondon G, Jain N, Jabbour E, Pullarkat V, Alkhateeb HB, Kantarjian HM, Greipp PT, Nakamura R, Kharfan- Dabaja MA, Champlin RE, Forman SJ, Shpall EJ, Litzow MR, Foran JM, Aldoss I, Koller PB, Kebriaei P. A Multicenter Analysis of Allogeneic Transplant Outcomes in Adults with Philadelphia-Like B-Cell Acute Lymphoblastic Leukemia in First Complete Remission. Transplant Cell Ther. 2024 Dec;30(12):1197-1205. PMID: 39332807 #Contributed equally
• Badar T, Narra R, Mims AS, Heckman MG, Shallis RM, Fahad S, Hunter C, Kota V, Othman TA, Jonas B, Desai S, de Camargo Correia GS, Patel A, DuVall AS, Palmisiano N, Curran E, Omer Z, Advani A, Atallah E, Litzow M. Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome- positive acute lymphoblastic leukemia: A multi-institutional study. Am J Hematol. 2024 Dec;99(12):2388-2391. PMID: 39253997
• Othman T, Frankel P, Allen P, Popplewell LL, Shouse G, Siddiqi T, Danilov AV, Ruel N, Daniels S, Peters L, Khoo S, Rosen ST, Sharon E, Villalona-Calero M, Ruel C, Tuscano J, Herrera AF. Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma. Haematologica. 2025 Jan 1;110(1):142-152. PMID: 39021209.
• Othman T, Koller P, Pourhassan H, Agrawal V, Ngo D, Tinajero J, Ali H, Cai JL, Mei M, Aribi A, Stein AS, Marcucci G, Forman SJ, Pullarkat V, Aldoss I. Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T-cell therapy in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Br J Haematol. 2024 Aug;205(2):711- 715. PMID: 38808512.
• Othman T#, Koller P#, Tsai NC, Yang D, Pourhassan H, Agrawal V, Ngo D, Chen J, Farol L, Spielberger R, Sahebi F, Al Malki MM, Cai JL, Sandhu KS, Mansour J, Salhotra A, Ali H, Aribi A, Arslan S, Marcucci G, Forman SJ, Stein AS, Nakamura R, Pullarkat V, Aldoss I, Mei M. Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2024 Sep;99(9):1680-1690. PMID: 38804599. #Contributed equally
• Othman T, Li S, Zhang J, Pourhassan H, Agrawal V, Ngo D, Chen J, Farol L, Sahebi F, Sandhu K, Spielberger R, Marcucci G, Forman SJ, Stein AS, Nakamura R, Pullarkat V, Mei M, Aldoss I, Koller P. Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2024 Aug;99(8):1636-1639. PMID: 38800943.
• Othman T#, Baird JH#, Pak S, Mei M, Herrera AF, Mansour J, Shouse G, Sahebi F, Spielberger R, Cai JL, Farol L, Godfrey J, Kallam A, Phillips T, Popplewell L, Siddiqi T, Forman S, Budde LE. Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma. Br J Haematol. 2024 Jul;205(1):368-372. PMID: 38797530. #Contributed equally
• Othman T, Lowsky R, Richman C, Hoeg R, Abedi M, Tuscano J. Yttrium-90 ibritumomab tiuxetan plus ATG/TLI for allogeneic hematopoietic cell transplantation in non-Hodgkin lymphoma. Bone Marrow Transplant. 2023 Oct;58(10):1143-1145. PMID: 37391654.
• Othman T, Quan MA, Zhang S, Gaut D, Young PA, Mahmood O, Abdulhaq H, Shieh K, Reid J, Brem EA, Hariharan N, Heyman B, Tuscano J. Impact of Thiotepa-Based Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma in First Complete Remission: A University of California Hematologic Malignancies Consortium Retrospective Analysis. Clin Lymphoma Myeloma Leuk. 2023 Oct;23(10):749-756. PMID: 37336714.
• Othman T, Penaloza J, Zhang S, Daniel CE, Gaut D, Oliai C, Brem EA, Baweja A, Ly J, Reid J, Pinter-Brown L, Lee M, Abdulhaq H, Tuscano J. R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis. Clin Lymphoma Myeloma Leuk. 2022 Oct;22(10):e947- e957. PMID: 35858904.
• Othman T#, Moskoff BN#, Ho G, Tenold ME, Azenkot T, Krackeler ML, Fisch SC, Potter LA, Kaesberg PR, Welborn JL, Wun T, Esteghamat NS, Hoeg RT, Rosenberg AS, Abedi M, Tuscano JM, Jonas BA. Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center. Leuk Res. 2022 Aug;119:106885. PMID: 35738024. #Contributed equally